Security reinforced at the specified location by VFA
The Association of Research-Based Pharmaceutical Manufacturers (vfa) recently held a discussion titled "Strong at the Location - Live" before the federal election in Germany. The event, which served as a platform for exchange of ideas and perspectives, centred on key discussion points around Germany’s position as an economic and innovative hub, the resilience of its healthcare system, and the future of the pharmaceutical industry.
- Germany's Role as an Economic and Innovation Location: The event emphasized Germany’s significance as a leading pharmaceutical and biotech hub in Europe. Discussions focused on maintaining and strengthening Germany’s attractiveness for pharmaceutical companies through supportive policies, investment in R&D, and fostering partnerships between industry, academia, and government.
- Healthcare System Resilience: The resilience of Germany’s healthcare system was a critical topic, especially in light of challenges posed by global health crises such as the COVID-19 pandemic. The panel underscored the need for robust supply chains, digitalization, and increased preparedness to ensure uninterrupted access to medicines and health services.
- Political and Regulatory Environment Ahead of the Federal Election: Since the event was held just before the federal election, a key focus was on what political stakeholders and future policymakers could do to support the pharmaceutical industry. Participants debated regulatory frameworks, pricing policies, and approval processes, stressing that streamlined regulations and supportive legislation are essential to sustain innovation and competitive advantage.
- Future of the Pharmaceutical Location in Germany: The discussion included strategies to secure Germany’s long-term leadership in pharmaceutical research and manufacturing, including investment incentives, talent retention, and enhancing cooperation within the European and global pharmaceutical landscape. The importance of digital transformation and sustainability in pharmaceutical production were also highlighted as future pillars.
Overall, the event served as a platform for industry leaders, policymakers, and experts to exchange views on aligning political will with industry needs to keep Germany strong as a pharmaceutical location—ensuring economic growth, innovation, and a resilient healthcare system in the years ahead. The discussion highlighted the role of the pharmaceutical industry in shaping the future of the healthcare system in Germany.
- The event emphasized the importance of finance and business in the pharmaceutical industry, particularly in sustaining innovation, attracting investments, and fostering partnerships between different sectors for the growth of Germany as a leading pharmaceutical location.
- A discussion on the future of medical-conditions treatment and diagnosis was held, focusing on the role of science and research-based innovations in improving health-and-wellness outcomes, and the need for continued investment in R&D to address unmet medical needs.
- Among the key topics of the forum was an analysis of the strategic role played by the pharmaceutical industry in medical-conditions management, with a focus on reducing costs, ensuring accessibility, and enhancing patient outcomes through cooperation and collaboration between industry, medical professionals, and regulatory authorities.
